Income Taxes (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| IncomeTaxLineItems [Line Items] |
|
| Schedule of Income Tax Benefit |
The
Company adopted ASU 2023-09 on a prospective basis beginning with the year ended December 31, 2025. The following table presents the
required disclosure pursuant to ASU 2023-09 and reconciles the U.S. federal statutory tax amount and rate to the actual effective amount
and rate for the year ended December 31, 2025:
Schedule
of Reconciliation of U.S Federal Statutory Tax and Effective Amount and Rate
| | |
2025 | |
| | |
Amount | | |
Percent | |
| U.S federal statutory tax rate | |
$ | (1,084 | ) | |
| 21.0 | % |
| Changes in valuation allowances | |
| 1,018 | | |
| (19.7 | )% |
| Nontaxable or nondeductible items | |
| | | |
| | |
| Stock-based compensation | |
| 63 | | |
| (1.2 | )% |
| Other | |
| 3 | | |
| (0.1 | )% |
| Effective tax rate | |
$ | - | | |
| - | % |
|
| Schedule of Reconciliation of Federal Statutory Income Tax Rate To Effective Income Tax Rate |
The
following table presents the required disclosure prior to the adoption of ASU 2023-09 and reconciles the U.S. federal statutory income
tax rate to the actual effective income tax rate for the years ended December 31, 2024:
Schedule
of Reconciliation of Federal Statutory Income Tax Rate To Effective Income Tax Rate
| | |
2024 | |
| Income tax computed at federal statutory tax rate | |
| 21.0 | % |
| State taxes, net of federal benefit | |
| 5.5 | % |
| Research and development credits | |
| 5.8 | % |
| Expiration of stock options | |
| (7.7 | )% |
| Permanent differences | |
| (2.4 | )% |
| Limitations on credits and net operating losses | |
| (1.2 | )% |
| Change in valuation allowance | |
| (21.0 | )% |
| Effective tax rate | |
| - | |
|
| Schedule of Components of Deferred Tax Assets |
The
significant components of the Company’s deferred tax assets as of December 31, 2025 and 2024 were as follows:
Schedule
of Components of Deferred Tax Assets
| | |
2025 | | |
2024 | |
| Deferred tax assets: | |
| | | |
| | |
| Net operating loss carryforwards | |
$ | 19,311 | | |
$ | 16,116 | |
| Capitalized research and experimental costs | |
| 5,708 | | |
| 7,836 | |
| Research and development credit carryforwards | |
| 1,945 | | |
| 1,945 | |
| Capitalized start-up expenses | |
| 117 | | |
| 135 | |
| Stock-based compensation | |
| 108 | | |
| 183 | |
| Other | |
| 660 | | |
| 309 | |
| Total deferred tax assets | |
| 27,849 | | |
| 26,524 | |
| Valuation allowance | |
| (27,849 | ) | |
| (26,524 | ) |
| Net deferred tax assets | |
$ | - | | |
$ | - | |
|
| Schedule of Roll-forward of Gross Uncertain Tax Positions |
The
roll-forward of the Company’s gross uncertain tax positions is as follows:
Schedule
of Roll-forward of Gross Uncertain Tax Positions
| | |
Gross
Uncertain
Tax Position | |
| Balance — January 1, 2024 | |
$ | 505 | |
| Additions for current year tax positions | |
| 139 | |
| Balance — December 31, 2024 | |
| 644 | |
| Additions for current year tax positions | |
| - | |
| Balance — December 31, 2025 | |
$ | 644 | |
|
| Eos SENOLYTIXS Inc [Member] |
|
| IncomeTaxLineItems [Line Items] |
|
| Schedule of Income Tax Benefit |
The
income tax benefit for the periods ended December 31, 2025 and 2024 consists of the following:
Schedule
of Income Tax Benefit
| | |
12/31/2025 | | |
12/31/2024 | |
| | |
December 31, | |
| | |
12/31/2025 | | |
12/31/2024 | |
| Current | |
$ | - | | |
$ | - | |
| Deferred | |
| (64,000 | ) | |
| (19,000 | ) |
| Change in valuation allowance | |
| 64,000 | | |
| 19,000 | |
| Net deferred tax assets | |
$ | - | | |
$ | - | |
|
| Schedule of Reconciliation of Federal Statutory Income Tax Rate To Effective Income Tax Rate |
In
accordance with ASU 2023-09, reconciling items greater than 5% of the statutory tax rate are presented separately. Amounts below this
threshold are aggregated within “Other.”
Schedule
of Reconciliation of Federal Statutory Income Tax Rate To Effective Income Tax Rate
| | |
Amount | | |
% | | |
Amount | | |
% | |
| | |
December 31, 2025 | | |
December 31, 2024 | |
| | |
Amount | | |
% | | |
Amount | | |
% | |
| U.S. federal statutory tax rate | |
$ | 53,000 | | |
| (21.0 | ) | |
$ | 16,000 | | |
| (21.0 | ) |
| State taxes, net of federal benefit | |
| 11,000 | | |
| (4.2 | ) | |
| 3,000 | | |
| (3.8 | ) |
| Change in valuation allowance | |
| (64,000 | ) | |
| 25.2 | | |
| (19,000 | ) | |
| 24.8 | |
| Net | |
$ | - | | |
| 0 | % | |
$ | - | | |
| 0 | % |
|
| Schedule of Components of Deferred Tax Assets |
The
primary component of the Company’s December 31, 2025 and 2024 deferred tax assets and related valuation allowances is its net operating
loss carryforwards.
Schedule
of Components of Deferred Tax Assets
| | |
2025 | | |
2024 | |
| | |
December 31, | |
| | |
2025 | | |
2024 | |
| Net operating loss carryforwards | |
$ | 83,000 | | |
$ | 19,000 | |
| Change in valuation allowance | |
| (83,000 | ) | |
| (19,000 | ) |
| Deferred tax asset | |
$ | - | | |
$ | - | |
|
| Schedule of Income Taxes Paid |
Income
taxes paid (Disaggregated) 2025:
Schedule
of Income Taxes Paid
| | |
Amount | |
| | |
(in
dollars) | |
| U.S. Federal | |
$ | - | |
| U.S. State | |
$ | - | |
| Foreign | |
$ | - | |
| Total Income Taxes Paid | |
$ | - | |
|